Evodenoson

Evodenoson is a selective agonist of the A2A adenosine receptor. Evodenoson’s primary actions include reducing inflammatory responses, decreasing intestinal fluid secretion, edema, tissue damage, and neutrophil infiltration induced by Clostridium difficile toxin A. Evodenoson’s protective effect is achieved by reducing myeloperoxidase (MPO) and adenosine deaminase (ADA) activities, and by lowering the production of tumor necrosis factor-alpha (TNF-α) [1].

Product Specifications

CAS Number

[844873-47-8]

Product Name Alternative

ATL 313; DE 112

UNSPSC

12352005

Target

Adenosine Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein

Applications

COVID-19-immunoregulation

Field of Research

Infection; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/evodenoson.html

Purity

99.9

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

O[C@H]1[C@@H](O[C@@H]([C@H]1O)C(NC2CC2)=O)N3C4=NC(C#CCC5CCN(CC5)C(OC)=O)=NC(N)=C4N=C3

Molecular Formula

C23H29N7O6

Molecular Weight

499.52

References & Citations

[1]Cavalcante IC, et al. Effect of novel A2A adenosine receptor agonist ATL 313 on Clostridium difficile toxin A-induced murine ileal enteritis. Infect Immun. 2006 May;74 (5) :2606-12.